EN | RU
EN | RU

Help Support

Back

Use of second biologic therapy following the stop of a TNFi as first biologic in rheumatoid arthritis patients

Use of second biologic therapy following the stop of a TNFi as first biologic in rheumatoid arthritis patients Use of second biologic therapy following the stop of a TNFi as first biologic in rheumatoid arthritis patients
Use of second biologic therapy following the stop of a TNFi as first biologic in rheumatoid arthritis patients Use of second biologic therapy following the stop of a TNFi as first biologic in rheumatoid arthritis patients

This study aimed to evaluate the outcome of the second bDMARD (non-TNFi i.e rituximab, abatacept or tocilizumab, used individually) and TNFi) following the stop of an initial non-TNFi bDMARD.

See All

Key take away

Given the lack of studies concerning the efficacy of a second biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in patients with rheumatoid arthritis (RA), this study comprising of 620 RA patients provided a reasonable drug survival and primary response for second bDMARDs after stopping initial bDMARDs.

Background

This study aimed to evaluate the outcome of the second bDMARD (non-TNFi i.e rituximab, abatacept or tocilizumab, used individually) and TNFi) following the stop of an initial non-TNFi bDMARD.

Method

Overall, 620 RA patients were recognised who initially began with non-TNFi treatment and later switched to bDMARD (86 patients on ABA, 40 patients on RTX, 67 patients on TCZ and 427 patients on TNFi). For the second bDMARD, drug survival (at half and 1 year), and primary response (at half year) were examined.

Result

About 70% patients remained on the treatment at 6 months after initiation of their second bDMARD and about 50% patients remained on the treatment at 12 months. As per the disease activity score, DAS28, less than 33% of patients were still on their second bDMARD; with low disease activity at a period of 6 months. The corresponding proportion was somewhat higher (40%) in patients whose second bMDARD was a TNFI.

Conclusion

The use of a second bDMARD in RA patients after switching from a non-TNFi bDMARD as first bDMARD leads to a modest drug survival and primary response. Some patients may profit from TNFi when used following the stop of a non-TNFi as first bDMARD.

Source:

The Journal of Rheumatology

Article:

Effectiveness of a second biologic after failure of a non-tumor necrosis factor inhibitor as first biologic in rheumatoid arthritis

Authors:

Katerina Chatzidionysiou et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en ua
Try: